Although coagulopathy is a well-known complication of severe niacin-induced hepatotoxic reaction, it is not found in patients with minimal aminotransferase level elevations. Three patients with significant clotting factor synthesis deficiency and coagulopathy (prothrombin times, >1.5 times control) from sustained-release niacin had only mild aminotransferase level elevations (1.5 to 2.0 times normal). In each case, protein deficiency, coagulopathy, and aminotransferase level elevation resolved promptly after withdrawal of niacin therapy. In one case, this syndrome recurred after rechallenge with sustained-release niacin, whereas the coagulopathy did not recur in a second patient rechallenged with crystalline niacin. Deficiency in protein synthesis, including coagulation factors, and coagulopathy are unrecognized complications of sustained-release niacin therapy. These cases indicate the need to measure prothrombin times routinely in patients who develop even mild aminotransferase level elevation while receiving sustainedrelease niacin therapy. These data are important in light of the increasing use of sustained-release niacin in the treatment of patients with lipid disorders.
(Arch Intern Med. 1992;152:861-863)
Dearing BD, Lavie CJ, Lohmann TP, Genton E. Niacin-Induced Clotting Factor Synthesis Deficiency With Coagulopathy. Arch Intern Med. 1992;152(4):861–863. doi:10.1001/archinte.1992.00400160147030
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.